AbbVie Inc. (ABBV) · Oct 30, 2026 · Earnings

AbbVie earnings beat as Skyrizi and Rinvoq offset Humira slide

Beat — Adjusted EPS $3.82 vs ~$3.74 consensus; FY guide midpoint $13.97 vs $13.86 prior

AbbVie earnings beat on revenue and adjusted EPS, with stronger immunology growth and a raised 2026 outlook despite Humira erosion.

AbbVie is in the post-Humira replacement phase: building its next growth leg around Skyrizi and Rinvoq while expanding its neuroscience, oncology and immunology pipeline. Skyrizi and Rinvoq each represented more than 10% of AbbVie's 2025 revenue, and together accounted for roughly 42% of total revenue.

The quarter cleared expectations. Adjusted diluted EPS was $3.82 versus a published consensus of roughly $3.74, while revenue was $17.404 billion versus approximately $17.32 billion expected. The EPS figure included a disclosed $0.11 acquired-I​​PR&D charge, so the underlying result was stronger than the headline number suggests.

Q3 2026Q3 2025Consensus / Prior guide
Revenue (Net Revenues)$17.404B (+10.3%)$15.776B~$17.32B consensus
Adjusted diluted EPS (Financial Results)$3.82 (+105.4%)$1.86~$3.74 consensus
FY adjusted diluted EPS guide (Guidance)$13.95-$13.99—$13.76-$13.96 prior

The growth engine is doing the heavy lifting. Immunology revenue rose 16.3% to $9.165 billion, led by Skyrizi at $5.776 billion, up 22.7%, and Rinvoq at $2.706 billion, up 23.9%. Humira still fell 31.2% to $683 million, but the replacement products more than compensated.

The portfolio is broadening beyond immunology, but unevenly. Neuroscience grew 19.4%, with strong contributions from Vraylar, Ubrelvy, Qulipta and the early-stage Vyalev launch. Oncology was essentially flat at 0.8% growth, while Aesthetics declined 1.4%, showing that the quarter's strength was concentrated in the newer immunology and neuroscience franchises rather than broad-based across every business.

Management raised the full-year outlook, but the increase is narrow. The adjusted EPS range moved from $13.76-$13.96 to $13.95-$13.99. The new range signals confidence after the beat, though its midpoint rises only about $0.11 and the guidance excludes unpredictable future acquired IPR&D and milestone charges.

The pipeline update strengthens the longer-term replacement story, not near-term earnings. The filing adds a Skyrizi Crohn's disease approval, positive Phase 3 data for lutikizumab in hidradenitis suppurativa, a new Parkinson's approval for Juvmo, positive Qulipta menstrual-migraine data and encouraging oncology readouts. The Apogee acquisition itself is no longer new—it closed on September 3, 2026—but the quarter shows AbbVie beginning to integrate that deal into a broader immunology strategy.

Bottom line: This was a genuine earnings beat with a raised outlook, and the core Skyrizi-Rinvoq franchise is more than offsetting Humira's decline. The event materially reinforces AbbVie's replacement-growth story, although the pipeline benefits remain mostly future rather than current revenue.

What to watch next

Lutikizumab HS regulatory submissions, second half 2027

Original filing on SEC EDGAR

More AbbVie Inc. news

AbbVie earnings beat as Skyrizi and Rinvoq offset Humira slide | ABBV Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.